June 5, 2024 – McKesson Company introduced that the board of administrators of McKesson Dr. Deborah Dunsire has been elected director and member of the Compensation and Expertise Committee and Finance Committee, efficient June 3, 2024. Dr. Dunsire joins the board with greater than 30 years of expertise main massive, matrix organizations within the biopharmaceutical, oncology and different specialty industries.

She not too long ago retired from her position as president and CEO of H. Lundbeck A/S, a biopharmaceutical firm specializing in growing and delivering transformative therapies for mind ailments. Beforehand, she held management positions at a number of pharmaceutical corporations, together with XTuit Prescribed drugs, FORUM Prescribed drugs, Millennium: The Takeda Oncology Firm and Millennium Prescribed drugs. Dr. Dunsire began her profession as a common practitioner in Johannesburg, South Africa.

Dr. Dunsire presently serves on the boards of administrators of Syros Prescribed drugs, Inc. and Ultragenyx Pharmaceutical Inc. She obtained her medical diploma from the College of Witwatersrand in Johannesburg, South Africa.

Board members Linda Mantia, who’s now not unbiased, and Susan Salka, who served on the board for nearly ten years, is not going to search re-election on the 2024 Common Assembly of Shareholders. Upon the election of all proposed nominee administrators on the Annual Assembly, the scale of the board of administrators might be lowered to 11 members, 10 of whom are unbiased.

Study extra